<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The c-kit proto-oncogene is the receptor gene for the stem cell growth factor </plain></SENT>
<SENT sid="1" pm="."><plain>Little is known about the distribution and role of this gene product in malignant hematopoiesis </plain></SENT>
<SENT sid="2" pm="."><plain>We analysed here the expression of c-kit in <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>), including <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET), <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), and idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (IMF) and in the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The c-kit expression of peripheral blood mononuclear cells was measured both at the <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> level using Northern analysis, the <z:chebi fb="40" ids="33697">RNA</z:chebi> dot blot technique with densitometric quantification, the sensitive reverse transcription polymerase chain reaction, and at the protein level using immunofluorescence with monoclonal antibodies </plain></SENT>
<SENT sid="4" pm="."><plain>There was a statistically significant increase in c-kit messenger levels in <z:mp ids='MP_0005481'>CML</z:mp>, ET, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, IMF, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as compared with controls (healthy volunteers) </plain></SENT>
<SENT sid="5" pm="."><plain>The percentage of c-kit protein expressing cells was also higher than in the controls in these disorders </plain></SENT>
<SENT sid="6" pm="."><plain>There was a significant correlation of the c-kit protein expression with the CD34 antigen of the cells </plain></SENT>
<SENT sid="7" pm="."><plain>Expression correlated with the phase of the disease, being highest in the <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:mp ids='MP_0005481'>CML</z:mp> and in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/RAEBt phases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The data suggest that increased amounts of circulating stem/progenitor cells with c-kit receptor are found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>It is possible that elevated c-kit expression could maintain the affected clone in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>